Prithipal Singh Sells 2,000 Shares of Abaxis Inc (ABAX) Stock
Abaxis Inc (NASDAQ:ABAX) Director Prithipal Singh sold 2,000 shares of Abaxis stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Prithipal Singh also recently made the following trade(s):
- On Wednesday, January 31st, Prithipal Singh sold 2,000 shares of Abaxis stock. The stock was sold at an average price of $74.63, for a total transaction of $149,260.00.
Shares of Abaxis Inc (NASDAQ ABAX) opened at $71.69 on Friday. Abaxis Inc has a 52 week low of $43.66 and a 52 week high of $78.53. The firm has a market cap of $1,627.22, a price-to-earnings ratio of 66.38, a price-to-earnings-growth ratio of 11.77 and a beta of 1.27.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, March 1st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, February 28th. Abaxis’s dividend payout ratio (DPR) is currently 59.26%.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. We Are One Seven LLC bought a new stake in Abaxis in the fourth quarter valued at $108,000. MetLife Investment Advisors LLC bought a new stake in Abaxis in the fourth quarter valued at $552,000. Gotham Asset Management LLC bought a new stake in Abaxis in the fourth quarter valued at $203,000. PEAK6 Investments L.P. bought a new stake in Abaxis in the fourth quarter valued at $202,000. Finally, Teachers Advisors LLC increased its stake in Abaxis by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 43,798 shares of the medical research company’s stock valued at $2,169,000 after purchasing an additional 1,050 shares in the last quarter. 96.64% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on ABAX. Stifel Nicolaus lifted their target price on shares of Abaxis from $48.00 to $57.00 and gave the stock a “hold” rating in a research note on Friday, January 26th. BidaskClub downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Zacks Investment Research raised shares of Abaxis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Northcoast Research raised shares of Abaxis from a “neutral” rating to a “buy” rating in a research note on Friday, January 5th. Finally, Canaccord Genuity reissued a “hold” rating and set a $65.00 target price on shares of Abaxis in a research note on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $62.30.
COPYRIGHT VIOLATION NOTICE: “Prithipal Singh Sells 2,000 Shares of Abaxis Inc (ABAX) Stock” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/03/11/prithipal-singh-sells-2000-shares-of-abaxis-inc-abax-stock.html.
Abaxis Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.